KPTI News and Press, Karyopharm Therapeutics Inc. From 02/07/22

AGCO, ARMK, AVNT, OTCQX:BNPQF, BP, CARR, CEIX, CNC, CNHI, COTY, CVE, DD, FISV, HAE, HLI, HOG, INCY, IT, J, KKR, KPTI, LEA, MAS, MBUU, MFGP, NRZ, OTCPK:NSANY, PFE, POLY, QTNT, OTCPK:SFTBY, SPGI, SQNS, SYY, TDG, TMHC, TRI, VIRT, VSH, WMG, WTW For Seeking Alpha's full earnings season calendar,&#...

Karyopharm to Report Fourth Quarter and Full Year 2021 Financial Results on February 8, 2022 -- Conference Call Scheduled for Tuesday, February 8, 2022, at 8:30 a.m. ET -- PR Newswire NEWTON, Mass. , Feb. 2, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (...

Karyopharm Therapeutics (NASDAQ:KPTI) granted 15 newly-hired employees stock options to buy a total of 124.5K common shares. The stock options were granted as inducements material and have an exercise price of $8.90 per share. For further details see: Karyopharm grants st...

Karyopharm Receives Orphan Drug Designation from FDA for Eltanexor for the Treatment of Myelodysplastic Syndromes PR Newswire NEWTON, Mass. , Jan. 24, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pion...

Karyopharm to Present at B. Riley Securities Oncology Investor Conference PR Newswire NEWTON, Mass. , Jan. 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today anno...

Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer PR Newswire NEWTON, Mass. , Jan. 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced t...

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives - Unaudited Net Product Revenues of Approximately $29.7 Million for Fourth Quarter 2021 and Approximately $98.3 Million for the Full Year 2021- - Co...

Karyopharm to Present at 40th Annual J.P. Morgan Healthcare Conference PR Newswire NEWTON, Mass. , Jan. 4, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announce...

Karyopharm Therapeutics (NASDAQ:KPTI) and privately-held Menarini Group have entered into an exclusive licensing agreement whereby Menarini will commercialize Nexpovio (selinexor) for the treatment of oncology indications in Europe, Latin America and other key countries. KPTI s...

Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology...